Cargando…
Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: A real‐world database study
BACKGROUND: Administration of doxorubicin by continuous intravenous (CIV) infusion, versus bolus (BOL) administration, has been proposed to mitigate the risk of cardiac events. This study used real‐world data to explore the association between mode of doxorubicin administration and duration of treat...
Autores principales: | Cranmer, Lee D., Hess, Lisa M., Sugihara, Tomoko, Muntz, Howard G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875654/ https://www.ncbi.nlm.nih.gov/pubmed/35852051 http://dx.doi.org/10.1002/cnr2.1681 |
Ejemplares similares
-
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020) -
Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin
por: Li, Jieli, et al.
Publicado: (2020) -
Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial
por: Van Tine, Brian A, et al.
Publicado: (2022) -
Real-World Outcomes and Factors Associated With the Second-Line
Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal
Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019) -
Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer
por: Alhaja, Maher, et al.
Publicado: (2023)